SUCCESSOR-2 #EHA2026 MeziKd vs Kd in anti-CD38 LEN-exposed RRMM: 📊 PFS 18.0 vs 8.3 months (HR 0.48 | p<0.0001) ✅ ORR 80% | ≥CR 27% | VGPR doubled, CR tripled Not competing with bispecifics or CAR-T. Complementing them :earlier, broader, more scalable #mmsm

Interim analysis of #EHA2026: outstanding. But the protocol is now on an unplanned pause. Temporary primary endpoint: Brazil advancing 🇧🇷⚽ Safety Monitoring Committee has approved the decision. No futility concerns. #VaiBrasil #mmsm

#EHA2026 | MajesTEC-9 Phase 3 — RRMM 2L Tec vs PVd/Kd (post anti-CD38 leni): 📊 PFS: HR 0.29 | 18-mo 69.8% vs 26.9% 📊 ORR: 84.5% vs 54.2% 📊 ≥CR: 65.9% vs 36.4% 📊 MRD-neg: 86.4% vs 45.5% (evaluable) 📊 OS: HR 0.60 | 18-mo 79.2% vs 68.6% #MultipleMyeloma #mmsm

🔥 EHA2026 | Toxoplasmosis After Allo-HSCT Prof. Varun Mehra — Real-world infectious complications 🦠 Toxoplasmosis is uncommon but potentially devastating after allo-HSCT Around one-third of the global population may be seropositive for Toxoplasma gondii. In allo-HSCT, disease usually reflects reactivation in seropositive recipients rather than primary infection. 🧠 CNS toxoplasmosis is the key feared presentation MRI may show brain lesions that can mimic: 🧬 lymphoma/PTLD 🦠 fungal infection 🧫 bacterial abscess ⚠️ CNS relapse/metastatic disease 🎯 In immunocompromised patients, toxoplasmosis must remain in the differential. ⏱️ Timing after allo-HCT Median onset of toxoplasma infection/disease after allo-HCT: D 62 📌 Earlier than after solid organ transplant 📌 Infection usually precedes overt disease 📌 First positive PCR appears earlier in prospective screening studies 📌 Earlier onset occurs in patients receiving no prophylaxis 📌 90% of toxoplasmosis cases occur within 6 months after transplant. Primary infection in recipient-seronegative patients is extremely rare. 🧪 Toxo qPCR screening after allo-HCT: why it matters Despite limited randomized evidence, screening studies show: ✅ PCR can identify toxoplasma reactivation early in 6–32% of seropositive allo-HCT recipients ✅ Risk is highest before engraftment, when TMP-SMX prophylaxis is often not yet started ✅ Untreated infection frequently precedes disease ✅ Screening-based strategies appear to reduce toxoplasmosis-attributable mortality compared with historical outcomes 🧬 Who should be screened? Pre-transplant recipient toxoplasma serology is essential, regardless of donor serology. If serology is negative but uncertainty exists, repeat/check prior diagnostic serology when feasible. 📆 Screening schedule after allo-HSCT Start toxoplasma qPCR screening from D0. Screen at least weekly until D 100. Then at least every 2 weeks until D 180, adapted to follow-up frequency and intensity of immunosuppression. 💊 TMP-SMX remains central After engraftment, TMP-SMX prophylaxis for Pneumocystis jirovecii also provides toxoplasma protection. Suggested prophylaxis doses on the slide: TMP-SMX 80/400 mg daily or 160/800 mg three times per week ⚠️ When to continue qPCR screening despite TMP-SMX Continue/consider screening if: 🔸 Alternative non–TMP-SMX PJP prophylaxis is used 🔸 No prophylaxis 🔸 Poor compliance 🔸 Diarrhea or poor absorption 🔸 Ongoing intense immunosuppression 🧠 Clinical takeaway ✅ Toxoplasmosis after allo-HSCT is mainly an early reactivation disease ✅ Highest-risk window: D0–D180, especially pre-engraftment and before TMP-SMX ✅ qPCR surveillance can detect infection before clinical disease ✅ TMP-SMX is protective, but screening remains important when absorption/adherence/prophylaxis is unreliable ✅ CNS lesions post-HSCT should always trigger toxoplasma consideration in seropositive or unknown-status patients 📚 Source: EHA2026 Congress slides — From Conventional to Emerging Approaches: Evolving Infection Prevention Strategies in Allogeneic HSCT and Cellular Therapies; talk by Prof. Varun Mehra. Slide-cited references include Aerts R, Mehra V et al., Lancet Infectious Diseases 2024, Adekunle et al. 2021, Bories P, Bone Marrow Transplantation 2012, Conrad A et al., Clinical Microbiology and Infection 2016, and Montoya & Liesenfeld, Lancet 2004. #EHA2026 #HSCT #AlloHSCT #Toxoplasmosis #ToxoplasmaGondii #InfectionPrevention #TMP_SMX #PJPProphylaxis #ImmuneReconstitution #CellularTherapy #Hematology #KFSHRC #ESH #DrChokriBenLamine

#EHA2026: Anselamimab delivers a potential breakthrough in newly diagnosed κ AL #amylodosis ✅ 62% reduction in all-cause mortality (HR 0.38; P=0.012) ✅ 71% reduction in cardiovascular hospitalizations (IRR 0.29; P=0.028)

New EHA guidelines for HL: BRECAD is prioritized for younger patients, while N-AVD remains mainly positioned for patients >60 years. #EHA2026 @EHA_Hematology

#EHA2026 Linvoseltamab in R/R AL #amylodosis LINKER-AL2 study: 🔹 100% ≥VGPR 🔹 90% CR 🔹 Rapid reduction of involved 🔹 Renal response: 73% 🔹 Cardiac response: 50% 🔹 No hematologic progression 🔹 No DLTs reported ✅ CRS: 50% ✅ ICANS: 5% (G 1) ⚠️ Infections: 85% (G≥3: 25%)

A REAL-WORLD STUDY OF INOTUZUMAB OZOGAMICIN COMBINED WITH VENETOCLAX AS FRONTLINE THERAPY FOR NEWLY-DIAGNOSED PH-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH SEVERE COMORBIDITY #EHA26

Today's the day to catch up with my old friend and clinical discussion partner at Txagorritxu Hospital, the legendary @erperpersona , “El Coletas”! @TxagorritxuOsp #hematología #EHA2026

🔥 Etentamig in R/R AL amyloidosis ✅ 100% hematologic CR ✅ 100% MRD negativity (40 mg cohort) ✅ iFLC <10 mg/L in 7 days ✅ 83% cardiac responses ✅ No CRS at RP2D ✅ No ICANS ✅ No hematologic progression #Amyloidosis

#EHA2026 Predictors of CVAEs after anthracycline in #lymphoma #lymsm #CardioOnc

PV — When to Start/Switch Cytoreduction 🩸🔥 EHA2026 🟢 Low-risk PV basics Age <60 no prior thrombosis ➡️ Manage CV risk ❤️ ➡️ Aspirin 81–100 mg/day 💊 ➡️ Phlebotomy to keep Hct <45% 🩸 🚨 Cytoreduction in low-risk PV is NOT routine But becomes important when specific red flags appear ⚠️ ✅ ELN 2021: cytoreduction recommended 🩸 Strictly defined poor tolerance to phlebotomy 🫛 Symptomatic/progressive splenomegaly 📈 Persistent leukocytosis >20 ×10⁹/L 🤔 Cytoreduction to be considered 📈 Progressive persistent leukocytosis >15 ×10⁹/L 🩸 Extreme thrombocytosis and/or bleeding 🩸 Inadequate Hct control despite maintenance phlebotomy 🔥 Can be considered 😓 High symptom burden ❤️ Based on individual cardiovascular risk 💊 Preferred/used options ⭐ Ropeginterferon alfa-2b 💊 Peginterferon alfa-2a 💊 Hydroxyurea 🎯 Ruxolitinib mainly after HU intolerance/resistance 🔁 Switch from HU to 2nd-line therapy if inefficacy/intolerance 📌 Consider another cytoreductive drug if ≥1 ELN criterion met ❌ HU inefficacy examples 🩸 Vascular events: thrombosis or clinically relevant bleeding 😓 Persistent symptoms ≥6 months 📈 Persistent thrombocytosis >1000 ×10⁹/L 🫛 Progressive/symptomatic splenomegaly 📈 Progressive persistent leukocytosis 🩸 Need ≥6 phlebotomies/year to keep Hct <45% ⚠️ HU intolerance examples 🤢 Grade 3/4 or prolonged grade 2 non-hematologic toxicity 🩸 Hematologic toxicity at lowest effective HU dose 🌞 Non-melanoma skin cancers 🧠 Take-home PV management is not only Hct control. Think: thrombosis prevention symptom control phlebotomy burden leukocytosis spleen HU intolerance/resistance. #EHA2026 #PolycythemiaVera #PV #MPN #ELN #NCCN #Hydroxyurea #Ropeginterferon #Ruxolitinib #Hematology #KFSHRC